Tyrosine kinase inhibitors: the first decade.

@article{Agrawal2010TyrosineKI,
  title={Tyrosine kinase inhibitors: the first decade.},
  author={Meetu Agrawal and Ravin J. Garg and Julio C{\'e}sar Gal{\'a}n Cort{\'e}s and Alfonso Quint{\'a}s-Cardama},
  journal={Current hematologic malignancy reports},
  year={2010},
  volume={5 2},
  pages={
          70-80
        }
}
The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting this leukemogenic protein kinase, imatinib affords patients with CML sustained chromosomal remissions, which translate into prolonged survival. However, there has been concern over the emergence of resistance to imatinib, and some patients fail to respond or are intolerant of imatinib therapy because of… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS, ESTIMATED 43% COVERAGE

55 Citations

0510'11'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 55 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…